Search for a command to run...
The increasing prevalence of diabetes presents a substantial challenge to the U.S. health care system. Despite advancements in insulin formulations designed to mimic physiological patterns and the development of diabetes technologies such as continuous glucose monitoring, automated insulin delivery systems, and insulin pens, glycemic control remains suboptimal for the majority of individuals with diabetes. In addition to the clinical consequences of poor glycemic management, the rising costs associated with the treatment of diabetes-related complications impose a significant financial strain on the health care system. These findings highlight a critical unmet therapeutic need, particularly among individuals requiring prandial insulin therapy, and underscore the necessity for enhanced therapeutic strategies aimed at optimizing glycemic control and reducing the clinical and economic burden of diabetes. This review explores the primary barriers to effective glycemic management in patients with insulin-treated diabetes and evaluates the potential role of inhaled insulin therapy in facilitating safe and effective glycemic control.
Published in: Diabetes Technology & Therapeutics
Volume 28, Issue 1_suppl, pp. 14S-18S